Faster drug discovery leveraging digital human twin and quantum technology
Cost:
Reduced R&D costs at the pre-clinical stage
Speed:
Accelerated drug discovery and faster drugs from lab to counter
Quality:
Improved efficiency and effectiveness of drug development
Compliance:
Fully regulatory compliant with CDISC SEND standards
Driving research and pre-clinical studies leveraging HPC & QLM
Target identification and validation is too slow using traditional means of drug discovery. Atos provides the compute power and expertise to convert sequencing data and 3D-EM to actionable insights, followed by pre-clinical studies on human digital twin.
Atos can help in the complete value chain from research to pre-clincal studies and submission of SEND data for regulatory approval.
Advanced Computing
- Simplify workflows by processing data at the edge
- Deliver secure insights from IOT data in near real-time
- Federated learning platforms to create a collaborative eco system
- Data analytics capabilities that grow seamlessly
- Explore new hypotheses with Atos quantum computing simulator
Contact us to learn more about our Advanced Computing solutions >
Data intelligence
- Services to exchange, integrate and analyze the vast amounts of data collected from different sources into a global information infrastructure
- Sensors network to gather different physiological and environmental / localisation data
- Clinical decision support systems (CDSS)
- Algorithms to model data and simulate physiological behavior
Contact us to learn more about our Data intelligence solutions >
Simulation
Simulation capabilities for molecular modeling and protein folding to accelerate drug discovery
SEND support services
- SEND consulting
- SEND data conversion
- Data validation
- Migration services
- Compliance services
- Labeling
Key contacts
Harbir Sawhney
Global Portfolio Head, Life Sciences
Gauri Deshmukh
Senior Consultant, Life Sciences
Natalia Jiménez Lozano
Head of Atos Life Science Center of Excellence
